Literature DB >> 24533032

Adeno-associated virus structural biology as a tool in vector development.

Lauren M Drouin1, Mavis Agbandje-McKenna1.   

Abstract

Adeno-associated viruses (AAVs) have become important therapeutic gene delivery vectors in recent years. However, there are challenges, including intractable tissues/cell types and pre-existing immune responses, which need to be overcome for full realization of this system. This review addresses strategies aimed at improving AAV efficacy in the clinic through the creation of hybrid vectors that display altered or more targeted specific tissue tropisms, while also escaping recognition from host-derived neutralizing antibodies. Characterization of these viruses with respect to serotypes contributing to their capsid, using available 3D structures, enables the identification of regions critical for particular tropism and antigenic phenotypes. Structural information also allows for rational design of vectors with specific targeted tropisms for improved therapeutic efficacy.

Entities:  

Keywords:  adeno-associated virus; capsid structure; chimera; directed evolution; gene therapy; rational design; tissue tropism

Year:  2013        PMID: 24533032      PMCID: PMC3921901          DOI: 10.2217/fvl.13.112

Source DB:  PubMed          Journal:  Future Virol        ISSN: 1746-0794            Impact factor:   1.831


  110 in total

1.  Quantitative analysis of the packaging capacity of recombinant adeno-associated virus.

Authors:  J Y Dong; P D Fan; R A Frizzell
Journal:  Hum Gene Ther       Date:  1996-11-10       Impact factor: 5.695

2.  A conformational change in the adeno-associated virus type 2 capsid leads to the exposure of hidden VP1 N termini.

Authors:  Stephanie Kronenberg; Bettina Böttcher; Claus W von der Lieth; Svenja Bleker; Jürgen A Kleinschmidt
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

3.  Structure of adeno-associated virus serotype 8, a gene therapy vector.

Authors:  Hyun-Joo Nam; Michael Douglas Lane; Eric Padron; Brittney Gurda; Robert McKenna; Erik Kohlbrenner; George Aslanidi; Barry Byrne; Nicholas Muzyczka; Sergei Zolotukhin; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2007-08-29       Impact factor: 5.103

4.  Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis.

Authors:  S Uhrig; O Coutelle; T Wiehe; L Perabo; M Hallek; H Büning
Journal:  Gene Ther       Date:  2011-06-09       Impact factor: 5.250

Review 5.  Therapeutic gene targeting.

Authors:  R J Yáñez; A C Porter
Journal:  Gene Ther       Date:  1998-02       Impact factor: 5.250

6.  Structural insight into the unique properties of adeno-associated virus serotype 9.

Authors:  Michael A DiMattia; Hyun-Joo Nam; Kim Van Vliet; Matthew Mitchell; Antonette Bennett; Brittney L Gurda; Robert McKenna; Norman H Olson; Robert S Sinkovits; Mark Potter; Barry J Byrne; George Aslanidi; Sergei Zolotukhin; Nicholas Muzyczka; Timothy S Baker; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2012-04-11       Impact factor: 5.103

7.  Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2.

Authors:  E A Rutledge; C L Halbert; D W Russell
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

8.  Characterization of genome integrity for oversized recombinant AAV vector.

Authors:  Biao Dong; Hiroyuki Nakai; Weidong Xiao
Journal:  Mol Ther       Date:  2009-11-10       Impact factor: 11.454

9.  Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells.

Authors:  P L Hermonat; N Muzyczka
Journal:  Proc Natl Acad Sci U S A       Date:  1984-10       Impact factor: 11.205

10.  Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration.

Authors:  Francesca Simonelli; Albert M Maguire; Francesco Testa; Eric A Pierce; Federico Mingozzi; Jeannette L Bennicelli; Settimio Rossi; Kathleen Marshall; Sandro Banfi; Enrico M Surace; Junwei Sun; T Michael Redmond; Xiaosong Zhu; Kenneth S Shindler; Gui-Shuang Ying; Carmela Ziviello; Carmela Acerra; J Fraser Wright; Jennifer Wellman McDonnell; Katherine A High; Jean Bennett; Alberto Auricchio
Journal:  Mol Ther       Date:  2009-12-01       Impact factor: 11.454

View more
  24 in total

Review 1.  E Pluribus Unum: 50 Years of Research, Millions of Viruses, and One Goal--Tailored Acceleration of AAV Evolution.

Authors:  Dirk Grimm; Sergei Zolotukhin
Journal:  Mol Ther       Date:  2015-09-21       Impact factor: 11.454

2.  Taking a Hint from Structural Biology: To Better Understand AAV Transport across the BBB.

Authors:  Dan Wang; Guangping Gao
Journal:  Mol Ther       Date:  2018-02-07       Impact factor: 11.454

Review 3.  Strategies to circumvent humoral immunity to adeno-associated viral vectors.

Authors:  Longping V Tse; Sven Moller-Tank; Aravind Asokan
Journal:  Expert Opin Biol Ther       Date:  2015-06       Impact factor: 4.388

4.  Adeno-associated virus serotype 1 (AAV1)- and AAV5-antibody complex structures reveal evolutionary commonalities in parvovirus antigenic reactivity.

Authors:  Yu-Shan Tseng; Brittney L Gurda; Paul Chipman; Robert McKenna; Sandra Afione; John A Chiorini; Nicholas Muzyczka; Norman H Olson; Timothy S Baker; Jürgen Kleinschmidt; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2014-11-19       Impact factor: 5.103

Review 5.  Nanotherapy for Duchenne muscular dystrophy.

Authors:  Michael E Nance; Chady H Hakim; N Nora Yang; Dongsheng Duan
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-04-11

Review 6.  Therapeutic in vivo delivery of gene editing agents.

Authors:  Aditya Raguram; Samagya Banskota; David R Liu
Journal:  Cell       Date:  2022-07-06       Impact factor: 66.850

Review 7.  Systemic delivery of adeno-associated viral vectors.

Authors:  Dongsheng Duan
Journal:  Curr Opin Virol       Date:  2016-07-25       Impact factor: 7.090

Review 8.  Perspective on Adeno-Associated Virus Capsid Modification for Duchenne Muscular Dystrophy Gene Therapy.

Authors:  Michael E Nance; Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2015-10-15       Impact factor: 5.695

Review 9.  Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery.

Authors:  Natalie F Nidetz; Michael C McGee; Longping V Tse; Chengwen Li; Le Cong; Yunxing Li; Weishan Huang
Journal:  Pharmacol Ther       Date:  2019-12-11       Impact factor: 12.310

10.  Single amino acid insertion allows functional transduction of murine hepatocytes with human liver tropic AAV capsids.

Authors:  Marti Cabanes-Creus; Renina Gale Navarro; Sophia H Y Liao; Grober Baltazar; Matthieu Drouyer; Erhua Zhu; Suzanne Scott; Clement Luong; Laurence O W Wilson; Ian E Alexander; Leszek Lisowski
Journal:  Mol Ther Methods Clin Dev       Date:  2021-04-24       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.